ClinicalTrials.gg
CompletedNCT07573449Updated May 7, 2026

How [14C]-JNT-517 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Male Participants

A Phase 1 interventional study of [14C]-JNT-517 in Healthy Volunteers, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 9 months ago, and no results have been posted to the registry.
  • Registered 2 years 3 months after the study started (first participant enrolled Jan 2024, registered Apr 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this study is to determine the absorption, metabolism and excretion of [14C]-JNT-517 and to characterize and determine the metabolites present in plasma, urine, and feces in healthy male participants following a single oral administration.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.

Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (BMI) between 18.0 to 32.0 kilograms per square meter (kg/m\^2), inclusive.
  2. In good health at screening as determined by: a) Medical history, b) Physical examination, c) , d) Clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [e.g. suspicion of Gilbert's syndrome based on total and direct ] is not acceptable).
  3. History of a minimum of 1 bowel movement per day.
  4. Able to comprehend and are willing to sign the form (ICF) and abide by the study restrictions.

Exclusion criteria

Exclusion Criteria

  1. Use or intend to use any medications/products known to alter drug absorption, metabolism and excretion processes, including St. John's wort, within 30 days prior to dosing, considered to potentially impact participant safety or the objectives of the study, as determined by the investigator or designee.
  2. Alcohol consumption of >14 units per week.
  3. A Positive urine drug screen at screening or positive alcohol test result or positive urine drug screen at check-in.
  4. Participants having taken an drug within 30 days prior to screening.
  5. Participants who have previously been dosed in >2 radiolabeled drug studies in the last 12 months.
  6. Participants with exposure to significant diagnostic or therapeutic radiation (e.g. serial X-ray, computed tomography scan, barium meal).
  7. Previous exposure to JNT-517.

Note: Other protocol-specified inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    [14C]-JNT-517

    Participants receive a single dose of \[14C\]-JNT-517, orally, on Day 1

    Drug: [14C]-JNT-517

Interventions

06

What researchers measure

Primary outcomes

  1. Total Radioactivity Recovery (fet1-t2) in Urine and Feces

    Time frame: Up to Day 9

  2. Relative Amounts Of Radioactivity Excreted in Urine and Feces

    Time frame: Up to Day 9

  3. Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-∞) of [14C]-JNT-517 And Its Metabolites in Plasma

    Time frame: Up to Day 9

  4. Area Under The Concentration-Time Curve From Time Zero to The Time Of The Last Quantifiable Concentration (AUC0-tlast) of [14C]-JNT-517 And Its Metabolites in Plasma

    Time frame: Up to Day 9

  5. Maximum Plasma Concentration (Cmax) of [14C]-JNT-517 And Its Metabolites in Plasma

    Time frame: Up to Day 9

  6. Time to Reach Maximum (Peak) Observed Plasma Concentration (Tmax) of [14C]-JNT-517 And Its Metabolites in Plasma

    Time frame: Up to Day 9

  7. Apparent Terminal Elimination Half-Life (t½) of [14C]-JNT-517 And Its Metabolites in Plasma

    Time frame: Up to Day 9

  8. AUC₀-∞ of Total Radioactivity in Plasma And Whole Blood

    Time frame: Up to Day 9

  9. AUC₀-tlast of Total Radioactivity in Plasma And Whole Blood

    Time frame: Up to Day 9

  10. Cmax of Total Radioactivity in Plasma and Whole Blood

    Time frame: Up to Day 9

  11. Tmax of Total Radioactivity in Plasma and Whole Blood

    Time frame: Up to Day 9

  12. t½ of Total Radioactivity in Plasma and Whole Blood

    Time frame: Up to Day 9

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to Day 9

  2. Number of Participants With Clinically Significant Changes in Clinical Laboratory Test Parameters

    Time frame: Up to Day 9

  3. Number of Participants With Clinically Significant Changes in 12-lead Electrocardiogram (ECG) Parameters

    Time frame: Up to Day 9

07

Study locations

1 site
  • Fortrea Clinical Research Unit Inc.
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No — Anonymized individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Jan 2025, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2026
First posted
May 7, 2026
StartActual
Jan 22, 2024
Primary completionActual
Jan 22, 2025
CompletionActual
Feb 27, 2025
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07573449
Responsible party
Sponsor
First posted
May 7, 2026
Start date
Jan 22, 2024
Primary completion
Jan 22, 2025
Completion
Feb 27, 2025
Last update
May 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Repinatrabit

Start the discussion